Key facts
- General Sense’s last known valuation is $21.2M (Jul 2024).
- It has raised $10.4M; the latest was Later Stage VC ($1.2M) in Feb 2026.
- Notable investors include US National Science Foundation, SOSV, IndieBio, Asymmetry Ventures, Dolby Family Ventures — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for General Sense
- ·The full record, as it builds
Funding rounds
No funding rounds for General Sense are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About General Sense
Developer of a chemical sensing and analysis platform intended for detecting and interpreting molecular data for security and defense applications. The company's platform decodes biological olfactory processes to capture real-time chemical signals, converts inputs into structured data for analysis, integrates with AI models for detection and classification, supports continuous environmental monitoring, and enables scalable deployment beyond animal-based systems, enabling government and security organizations to identify chemical threats with improved detection consistency and scalability.
- Sector
- Healthcare
- HQ
- Media, PA, United States
- Founded
- 2020
- Employees
- 11
- Website
- generalsense.com/
- Ownership
- Privately Held (backing)
General Sense doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in General Sense shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on General Sense in its N-PORT filings yet. We sweep new filings monthly.